Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Giaccone, 2006, Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study, Clin Cancer Res, 12, 6049, 10.1158/1078-0432.CCR-06-0260 Jackman, 2007, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer, J Clin Oncol, 25, 760, 10.1200/JCO.2006.07.5754 Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 958, 10.1056/NEJMoa0904554 Zhu, 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21, J Clin Oncol, 26, 4268, 10.1200/JCO.2007.14.8924 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Cappuzzo, 2010, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 521, 10.1016/S1470-2045(10)70112-1 Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055 Wu, 2007, Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China, J Thorac Oncol, 2, 430, 10.1097/01.JTO.0000268677.87496.4c Lee, 2009, A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Park, 2007, Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer, J Clin Oncol, 25, 5233, 10.1200/JCO.2007.10.8134 Janne, 2010, Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406, Proc Am Soc Clin Oncol, 28 Rosell, 2011, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, Proc Am Soc Clin Oncol, 29, 476s Lynch, 2007, Epidermal growth factor receptor inhibitor–associated cutaneous toxicities: an evolving paradigm in clinical management, Oncologist, 12, 610, 10.1634/theoncologist.12-5-610 Reck, 2010, Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition, Onkologie, 33, 470, 10.1159/000317132